We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+17.01%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$5.66B
AUM Growth
+$1B
Cap. Flow
+$784M
Cap. Flow %
13.85%
Top 10 Hldgs %
43.17%
Holding
164
New
34
Increased
29
Reduced
25
Closed
18

Top Buys

Rank Stock Value
1
INTC icon
Intel
INTC
+$47.7M
2
ARGX icon
argenx
ARGX
+$47.4M
3
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$44.5M
4
IMA
ImageneBio Inc
IMA
+$44.2M
5
ACHL
Achilles Therapeutics
ACHL
+$37.3M

Top Sells

Rank Stock Value
1
GDS icon
GDS Holdings
GDS
+$89.7M
2
Z icon
Zillow
Z
+$66.8M
3
ONC
BeOne Medicines Ltd
ONC
+$49.7M
4
BABA icon
Alibaba
BABA
+$46.5M
5
QURE icon
uniQure
QURE
+$25.3M

Sector Composition

Rank Sector Weight
1 Healthcare 68.71%
2 Consumer Discretionary 8.71%
3 Technology 1.72%
4 Communication Services 0.79%
5 Real Estate 0.6%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INTC icon
26
Intel
INTC
$413B
$51.2M 0.9%
+800,000
New +$47.7M
AA icon
27
CALL
Alcoa
AA
$11.3B
$48.7M 0.86%
+1,500,000
New +$38M
SAGE
28
DELISTED
Sage Therapeutics
SAGE
$48.7M 0.86%
650,000
+250,000
+63% +$20.5M
IMA
29
ImageneBio Inc
IMA
$63.4M
$43.8M 0.77%
+129,126
New +$44.2M
BDTX icon
30
Black Diamond Therapeutics
BDTX
$95.1M
$39.9M 0.71%
1,646,517
– –
ALXO icon
31
ALX Oncology
ALXO
$262M
$38.7M 0.68%
525,000
+225,000
+75% +$17.7M
KRON
32
DELISTED
Kronos Bio
KRON
$38.6M 0.68%
1,317,954
– –
KRYS icon
33
Krystal Biotech
KRYS
$10.7B
$38.5M 0.68%
500,000
+262,500
+111% +$19.1M
CCXI
34
DELISTED
ChemoCentryx, Inc.
CCXI
$38.4M 0.68%
750,000
+100,000
+15% +$6.02M
ITOS
35
DELISTED
iTeos Therapeutics
ITOS
$37.4M 0.66%
1,094,047
– –
ACHL
36
DELISTED
Achilles Therapeutics
ACHL
$37.3M 0.66%
+2,255,375
New +$37.3M
FOLD
37
DELISTED
Amicus Therapeutics
FOLD
$37M 0.65%
3,750,000
+1,250,000
+50% +$19.3M
NBP
38
NovaBridge Biosciences American Depositary Shares
NBP
$186M
$36.4M 0.64%
750,000
+25,000
+3% +$1.36M
AVGO icon
39
Broadcom
AVGO
$1.76T
$34.8M 0.61%
+750,000
New +$34.7M
CERE
40
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$34.3M 0.61%
2,500,000
+217,900
+10% +$3.19M
BEKE icon
41
KE Holdings
BEKE
$17.7B
$34.2M 0.6%
600,000
-400,000
-40% -$25.1M
FCX icon
42
CALL
Freeport-McMoran
FCX
$86.2B
$32.9M 0.58%
+1,000,000
New +$32.4M
CAR icon
43
Avis
CAR
$5.47B
$32.6M 0.58%
+450,000
New +$23.3M
TPTX
44
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$29.6M 0.52%
312,700
-37,300
-11% -$4.44M
SWTX
45
DELISTED
SpringWorks Therapeutics
SWTX
$29.4M 0.52%
400,000
-50,000
-11% -$3.92M
ATRA icon
46
Atara Biotherapeutics
ATRA
$72.6M
$28.7M 0.51%
80,000
-32,000
-29% -$14.1M
DNLI icon
47
Denali Therapeutics
DNLI
$3.79B
$28.6M 0.5%
500,000
+100,000
+25% +$6.69M
FMTX
48
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
$28M 0.5%
1,000,000
+500,000
+100% +$18M
SLB icon
49
CALL
SLB Ltd
SLB
$72.7B
$27.2M 0.48%
1,000,000
– –
TRIL
50
DELISTED
Trillium Therapeutics Inc.
TRIL
$26.9M 0.47%
2,500,000
+400,000
+19% +$4.95M
1
2
3 4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q1 2021 Portfolio in Review

As of Q1 2021, Artal Group held 164 positions worth $5.66B, up 21% from $4.66B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Artal Group deployed $784M of net new capital in Q1 2021, opening 34 new positions and adding to 29 existing holdings. Its largest new stake was Intel: 800,000 shares worth $51.2M.

By sector, the portfolio is most concentrated in Healthcare at 69% of assets, down from 77% a quarter earlier, followed by Consumer Discretionary and Technology.

On the sell side, the largest reduction was GDS Holdings, an estimated $89.7M trimmed.

  • Artal Group's largest Q1 2021 buy was Intel: 800,000 shares worth $51.2M.
  • Artal Group added most to argenx in Q1 2021, an estimated $47.4M increase.
  • Artal Group's biggest Q1 2021 reduction was GDS Holdings, cutting an estimated $89.7M.
  • Artal Group fully exited Alibaba in Q1 2021, selling an estimated $46.5M.
  • Artal Group's ten largest holdings make up 43% of its $5.66B portfolio in Q1 2021.
  • Artal Group opened 34 new positions and closed 18 in Q1 2021.
  • Artal Group's portfolio value rose 21% quarter-over-quarter to $5.66B.

Based on Artal Group's 13F filing for Q1 2021, filed 14 May 2021.